PHILADELPHIA--(November 11, 2010) – Avid Radiopharmaceuticals’ acquisition by Eli Lilly and Company for up to $800 million is yet another example of the University City Science Center’s role as an engine of economic growth for the City of Philadelphia and the Greater Philadelphia region.
“Not only does the acquisition speak to the enormous potential of Avid’s technology, but it also cements both the Science Center’s role as a launching pad for new game-changing technologies and the Greater Philadelphia region’s strength as a life sciences cluster,” says Science Center President & CEO Stephen S. Tang, Ph.D. “We look forward to Avid’s continued presence on the Science Center campus for years to come.”
Download the full PDF
